183 related articles for article (PubMed ID: 25993709)
1. The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: A case-match study.
Nozari Y; Vosooghi S; Boroumand M; Poorhosseini H; Nematipour E; Salarifar M; Kassaian SE; Amirzadegan A; Alidoosti M; Haji-Zeinali AM; Saroukhani S
Anatol J Cardiol; 2015 May; 15(5):348-53. PubMed ID: 25993709
[TBL] [Abstract][Full Text] [Related]
2.
Osama S; Wirth F; Zahra G; Barbara C; Xuereb RG; Camilleri L; Azzopardi LM
Drug Metab Pers Ther; 2021 Jan; 37(2):155-161. PubMed ID: 34851561
[TBL] [Abstract][Full Text] [Related]
3. Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting.
Ma W; Liang Y; Zhu J; Chen T; Feng G; Yang Y; Liu X; Wang X
Atherosclerosis; 2016 Aug; 251():305-310. PubMed ID: 27450784
[TBL] [Abstract][Full Text] [Related]
4. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
Sibbing D; Stegherr J; Latz W; Koch W; Mehilli J; Dörrler K; Morath T; Schömig A; Kastrati A; von Beckerath N
Eur Heart J; 2009 Apr; 30(8):916-22. PubMed ID: 19193675
[TBL] [Abstract][Full Text] [Related]
6. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Buonamici P; Antoniucci D; Abbate R; Gensini GF
Am J Cardiol; 2009 Mar; 103(6):806-11. PubMed ID: 19268736
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Wei YQ; Wang DG; Yang H; Cao H
PLoS One; 2015; 10(7):e0132561. PubMed ID: 26147597
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19
Ruedlinger J; Prado Y; Zambrano T; Saavedra N; Bobadilla B; Potthoff M; Pérez L; Lanas F; Salazar LA
Biomed Res Int; 2017; 2017():5783719. PubMed ID: 28785581
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
[TBL] [Abstract][Full Text] [Related]
10. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
[TBL] [Abstract][Full Text] [Related]
12. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
[TBL] [Abstract][Full Text] [Related]
13. Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
Luo Y; Zhao YT; Verdo A; Qi WG; Zhang DF; Hu B
J Int Med Res; 2011; 39(5):2012-9. PubMed ID: 22118006
[TBL] [Abstract][Full Text] [Related]
14. Impact of dual antiplatelet therapy with adjusted-dose prasugrel on mid-term vascular response in patients undergoing elective percutaneous coronary intervention with everolimus-eluting stents.
Toba T; Shinke T; Otake H; Sugizaki Y; Takeshige R; Onishi H; Nagasawa A; Tsukiyama Y; Yanaka K; Nagano Y; Yamamoto H; Kawamori H; Matsuura A; Ishihara T; Matsumoto D; Igarashi N; Hayashi T; Yasaka Y; Kadotani M; Fujii T; Shite J; Okada M; Sakakibara T; Hirata KI
Heart Vessels; 2019 Jun; 34(6):936-947. PubMed ID: 30599059
[TBL] [Abstract][Full Text] [Related]
15. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.
Oh IY; Park KW; Kang SH; Park JJ; Na SH; Kang HJ; Koo BK; Jeong YH; Hwang JY; Kwak CH; Park Y; Hwang SJ; Ko YG; Shin DJ; Jang Y; Kim HS
Heart; 2012 Jan; 98(2):139-44. PubMed ID: 21700758
[TBL] [Abstract][Full Text] [Related]
16. Impacts of
Zhang M; Wang J; Zhang Y; Zhang P; Jia Z; Ren M; Jia X; Ma L; Gao M; Hou Y
Drug Des Devel Ther; 2020; 14():669-676. PubMed ID: 32109992
[TBL] [Abstract][Full Text] [Related]
17. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
[TBL] [Abstract][Full Text] [Related]
18. [Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention].
Tang XF; He C; Yuan JQ; Meng XM; Yang YJ; Qin XW; Qiao SB; Liu HB; Wu YJ; Yao M; Chen J; You SJ; Wu Y; Li JJ; Dai J; Chen JL; Gao RL; Chen ZJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jul; 39(7):617-20. PubMed ID: 22088240
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
[TBL] [Abstract][Full Text] [Related]
20. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
Bonello-Palot N; Armero S; Paganelli F; Mancini J; De Labriolle A; Bonello C; Lévy N; Maillard L; Barragan P; Dignat-George F; Camoin-Jau L; Bonello L
Am J Cardiol; 2009 Dec; 104(11):1511-5. PubMed ID: 19932784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
